Click here to get full coverage on 109,120 Options and 73,535 RSUs: Cytokinetics Grants Equity Inducements for New Hires - Stock Titan

109,120 Options and 73,535 RSUs: Cytokinetics Grants Equity Inducements for New Hires  Stock Titan

109,120 Options and 73,535 RSUs: Cytokinetics Grants Equity Inducements for New Hires - Stock Titan

Click here to get full coverage on Cytokinetics, Incorporated Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CYTK - Morningstar

Cytokinetics, Incorporated Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CYTK  Morningstar

Cytokinetics, Incorporated Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CYTK - Morningstar

Click here to get full coverage on New Highs: How interest rate cuts could boost CYTK stock - July 2025 Sentiment & High Return Trade Guides - Trung tâm Dự báo KTTV quốc gia

New Highs: How interest rate cuts could boost CYTK stock - July 2025 Sentiment & High Return Trade Guides  Trung tâm Dự báo KTTV quốc gia

New Highs: How interest rate cuts could boost CYTK stock - July 2025 Sentiment & High Return Trade Guides - Trung tâm Dự báo KTTV quốc gia

Click here to get full coverage on Cytokinetics (CYTK) CEO Blum sells $300k in shares - Investing.com

Cytokinetics (CYTK) CEO Blum sells $300k in shares  Investing.com

Cytokinetics (CYTK) CEO Blum sells $300k in shares - Investing.com

Click here to get full coverage on DEADLINE ALERT for CYTK, NX, JSPR, and KBR: The Law Offices - GlobeNewswire

DEADLINE ALERT for CYTK, NX, JSPR, and KBR: The Law Offices  GlobeNewswire

DEADLINE ALERT for CYTK, NX, JSPR, and KBR: The Law Offices - GlobeNewswire

Click here to get full coverage on Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug? - Yahoo Finance

Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?  Yahoo Finance

Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug? - Yahoo Finance

Click here to get full coverage on Disclosure Lawsuits and FDA Delays Might Change the Case for Investing in Cytokinetics (CYTK) - simplywall.st

Disclosure Lawsuits and FDA Delays Might Change the Case for Investing in Cytokinetics (CYTK)  simplywall.st

Disclosure Lawsuits and FDA Delays Might Change the Case for Investing in Cytokinetics (CYTK) - simplywall.st

Click here to get full coverage on Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire

Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit  PR Newswire

Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire

Click here to get full coverage on Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Globe and Mail

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)  The Globe and Mail

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Globe and Mail

Click here to get full coverage on Cytokinetics (CYTK) Stock Analysis: A 25.75% Potential Upside with Innovative Muscle Treatments - DirectorsTalk Interviews

Cytokinetics (CYTK) Stock Analysis: A 25.75% Potential Upside with Innovative Muscle Treatments  DirectorsTalk Interviews

Cytokinetics (CYTK) Stock Analysis: A 25.75% Potential Upside with Innovative Muscle Treatments - DirectorsTalk Interviews

Click here to get full coverage on Deadline Alert: Cytokinetics, Incorporated (CYTK) - GlobeNewswire

Deadline Alert: Cytokinetics, Incorporated (CYTK)  GlobeNewswire

Deadline Alert: Cytokinetics, Incorporated (CYTK) - GlobeNewswire

Click here to get full coverage on Cytokinetics (CYTK): Is the Current Market Valuation Overlooking the Company’s Long-Term Potential? - Yahoo Finance

Cytokinetics (CYTK): Is the Current Market Valuation Overlooking the Company’s Long-Term Potential?  Yahoo Finance

Cytokinetics (CYTK): Is the Current Market Valuation Overlooking the Company’s Long-Term Potential? - Yahoo Finance

Click here to get full coverage on Class Action Filed Against Cytokinetics, Incorporated - GlobeNewswire

Class Action Filed Against Cytokinetics, Incorporated  GlobeNewswire

Class Action Filed Against Cytokinetics, Incorporated - GlobeNewswire

Click here to get full coverage on CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC  GlobeNewswire

CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Click here to get full coverage on Cytokinetics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire

Cytokinetics Shareholder Alert: ClaimsFiler Reminds  GlobeNewswire

Cytokinetics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire

Click here to get full coverage on Cytokinetics (CYTK) Is Up 15.6% After Aficamten Outperforms Metoprolol in New Heart Data Has The Bull Case Changed? - Yahoo Finance

Cytokinetics (CYTK) Is Up 15.6% After Aficamten Outperforms Metoprolol in New Heart Data Has The Bull Case Changed?  Yahoo Finance

Cytokinetics (CYTK) Is Up 15.6% After Aficamten Outperforms Metoprolol in New Heart Data Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Cytokinetics Shareholder Alert By Former Louisiana Attorney - GlobeNewswire

Cytokinetics Shareholder Alert By Former Louisiana Attorney  GlobeNewswire

Cytokinetics Shareholder Alert By Former Louisiana Attorney - GlobeNewswire

Click here to get full coverage on CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - GlobeNewswire

CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics  GlobeNewswire

CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - GlobeNewswire

Click here to get full coverage on Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan - Yahoo Finance

Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan  Yahoo Finance

Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan - Yahoo Finance

Click here to get full coverage on HC Wainwright & Co. Reiterates Cytokinetics (CYTK) Buy Recommendation - Nasdaq

HC Wainwright & Co. Reiterates Cytokinetics (CYTK) Buy Recommendation  Nasdaq

HC Wainwright & Co. Reiterates Cytokinetics (CYTK) Buy Recommendation - Nasdaq

Click here to get full coverage on Cytokinetics (CYTK) Drops on $650-Million Debt Issuance - Yahoo Finance

Cytokinetics (CYTK) Drops on $650-Million Debt Issuance  Yahoo Finance

Cytokinetics (CYTK) Drops on $650-Million Debt Issuance - Yahoo Finance

Click here to get full coverage on CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm - Morningstar

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm  Morningstar

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm - Morningstar

Click here to get full coverage on Why Cytokinetics, Inc. (CYTK) Went Down On Friday - Yahoo Finance

Why Cytokinetics, Inc. (CYTK) Went Down On Friday  Yahoo Finance

Why Cytokinetics, Inc. (CYTK) Went Down On Friday - Yahoo Finance

Click here to get full coverage on December 19th Options Now Available For Cytokinetics (CYTK) - Nasdaq

December 19th Options Now Available For Cytokinetics (CYTK)  Nasdaq

December 19th Options Now Available For Cytokinetics (CYTK) - Nasdaq

Click here to get full coverage on Citi Lowers Cytokinetics (CYTK) PT to $77 Due to Uneventful Q2 2025 Earnings - Yahoo Finance

Citi Lowers Cytokinetics (CYTK) PT to $77 Due to Uneventful Q2 2025 Earnings  Yahoo Finance

Citi Lowers Cytokinetics (CYTK) PT to $77 Due to Uneventful Q2 2025 Earnings - Yahoo Finance

Click here to get full coverage on Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Elevance Health Inc. (NYSE: ELV); Fluor Corporation (NYSE: FLR); and Fly-E Group, Inc. (NASDAQ: FLYE): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire

Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Elevance Health Inc. (NYSE: ELV); Fluor Corporation (NYSE: FLR); and Fly-E Group, Inc. (NASDAQ: FLYE): Grabar Law Office is Investigating Claims on Your Behalf  GlobeNewswire

Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Elevance Health Inc. (NYSE: ELV); Fluor Corporation (NYSE: FLR); and Fly-E Group, Inc. (NASDAQ: FLYE): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire

Click here to get full coverage on Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT - Yahoo Finance

Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT  Yahoo Finance

Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT - Yahoo Finance

Click here to get full coverage on Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential (NASDAQ:CYTK) - Seeking Alpha

Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential (NASDAQ:CYTK)  Seeking Alpha

Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential (NASDAQ:CYTK) - Seeking Alpha

Click here to get full coverage on $CYTK stock is up 37% today. Here's what we see in our data. - Quiver Quantitative

$CYTK stock is up 37% today. Here's what we see in our data.  Quiver Quantitative

$CYTK stock is up 37% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Cytokinetics (CYTK) Is Up 13.0% After Positive Aficamten Data and Regulatory Scrutiny - Has The Bull Case Changed? - simplywall.st

Cytokinetics (CYTK) Is Up 13.0% After Positive Aficamten Data and Regulatory Scrutiny - Has The Bull Case Changed?  simplywall.st

Cytokinetics (CYTK) Is Up 13.0% After Positive Aficamten Data and Regulatory Scrutiny - Has The Bull Case Changed? - simplywall.st

Click here to get full coverage on Cytokinetics Merits A Speculative Buy Rating (NASDAQ:CYTK) - Seeking Alpha

Cytokinetics Merits A Speculative Buy Rating (NASDAQ:CYTK)  Seeking Alpha

Cytokinetics Merits A Speculative Buy Rating (NASDAQ:CYTK) - Seeking Alpha

Click here to get full coverage on Why Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to Buy - Yahoo Finance

Why Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to Buy  Yahoo Finance

Why Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to Buy - Yahoo Finance

Click here to get full coverage on Cytokinetics (CYTK) Stock Is Skyrocketing Tuesday: What's Driving The Action? - Benzinga

Cytokinetics (CYTK) Stock Is Skyrocketing Tuesday: What's Driving The Action?  Benzinga

Cytokinetics (CYTK) Stock Is Skyrocketing Tuesday: What's Driving The Action? - Benzinga

Click here to get full coverage on CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit - Eastern Progress

CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit  Eastern Progress

CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit - Eastern Progress

Click here to get full coverage on Do you own shares of CYTK? Robbins LLP Informs Investors of the Cytokinetics, Inc. Class Action Lawsuit - PR Newswire

Do you own shares of CYTK? Robbins LLP Informs Investors of the Cytokinetics, Inc. Class Action Lawsuit  PR Newswire

Do you own shares of CYTK? Robbins LLP Informs Investors of the Cytokinetics, Inc. Class Action Lawsuit - PR Newswire

Click here to get full coverage on ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages - GlobeNewswire

ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages  GlobeNewswire

ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages - GlobeNewswire

Click here to get full coverage on $550 Million Debt Offering: Cytokinetics Secures Funding for Breakthrough Drug Aficamten Launch - Stock Titan

$550 Million Debt Offering: Cytokinetics Secures Funding for Breakthrough Drug Aficamten Launch  Stock Titan

$550 Million Debt Offering: Cytokinetics Secures Funding for Breakthrough Drug Aficamten Launch - Stock Titan

Click here to get full coverage on 2.3 mL/kg/min Exercise Capacity Gain: Cytokinetics' Aficamten Outperforms 60-Year Standard in Heart Disease - Stock Titan

2.3 mL/kg/min Exercise Capacity Gain: Cytokinetics' Aficamten Outperforms 60-Year Standard in Heart Disease  Stock Titan

2.3 mL/kg/min Exercise Capacity Gain: Cytokinetics' Aficamten Outperforms 60-Year Standard in Heart Disease - Stock Titan

Click here to get full coverage on ‘Little Room Left for Doubt’: Cytokinetics (CYTK) Stock Soars on Successful Trial Results - TipRanks

‘Little Room Left for Doubt’: Cytokinetics (CYTK) Stock Soars on Successful Trial Results  TipRanks

‘Little Room Left for Doubt’: Cytokinetics (CYTK) Stock Soars on Successful Trial Results - TipRanks

Click here to get full coverage on CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm - PR Newswire

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm  PR Newswire

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm - PR Newswire

Click here to get full coverage on New Analyst Forecast: $CYTK Given $72.0 Price Target | CYTK Stock News - Quiver Quantitative

New Analyst Forecast: $CYTK Given $72.0 Price Target | CYTK Stock News  Quiver Quantitative

New Analyst Forecast: $CYTK Given $72.0 Price Target | CYTK Stock News - Quiver Quantitative

Click here to get full coverage on Cytokinetics posts trial data for cardiac drug (CYTK:NASDAQ) - Seeking Alpha

Cytokinetics posts trial data for cardiac drug (CYTK:NASDAQ)  Seeking Alpha

Cytokinetics posts trial data for cardiac drug (CYTK:NASDAQ) - Seeking Alpha

Click here to get full coverage on DEADLINE ALERT for LNTH and CYTK: The Law Offices of Frank - GlobeNewswire

DEADLINE ALERT for LNTH and CYTK: The Law Offices of Frank  GlobeNewswire

DEADLINE ALERT for LNTH and CYTK: The Law Offices of Frank - GlobeNewswire

Click here to get full coverage on Superior Heart Function Improvement: Cytokinetics' Aficamten Beats Standard Care in Major HCM Clinical Trial - Stock Titan

Superior Heart Function Improvement: Cytokinetics' Aficamten Beats Standard Care in Major HCM Clinical Trial  Stock Titan

Superior Heart Function Improvement: Cytokinetics' Aficamten Beats Standard Care in Major HCM Clinical Trial - Stock Titan

Click here to get full coverage on CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm - Business Wire

CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm  Business Wire

CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm - Business Wire

Click here to get full coverage on Barclays Raises Price Target for Cytokinetics (CYTK) to $82 | CY - GuruFocus

Barclays Raises Price Target for Cytokinetics (CYTK) to $82 | CY  GuruFocus

Barclays Raises Price Target for Cytokinetics (CYTK) to $82 | CY - GuruFocus

Click here to get full coverage on Cytokinetics: Specialty Franchise With Aficamten And Ulacamten (NASDAQ:CYTK) - Seeking Alpha

Cytokinetics: Specialty Franchise With Aficamten And Ulacamten (NASDAQ:CYTK)  Seeking Alpha

Cytokinetics: Specialty Franchise With Aficamten And Ulacamten (NASDAQ:CYTK) - Seeking Alpha

Click here to get full coverage on 82% Success Rate: Cytokinetics' Heart Drug Aficamten Outperforms Standard Treatment in Key Measures - Stock Titan

82% Success Rate: Cytokinetics' Heart Drug Aficamten Outperforms Standard Treatment in Key Measures  Stock Titan

82% Success Rate: Cytokinetics' Heart Drug Aficamten Outperforms Standard Treatment in Key Measures - Stock Titan

Click here to get full coverage on Cytokinetics, Incorporated (CYTK) Stock Analysis: Aiming for a 48% Upside with Promising Biotech Innovations - DirectorsTalk Interviews

Cytokinetics, Incorporated (CYTK) Stock Analysis: Aiming for a 48% Upside with Promising Biotech Innovations  DirectorsTalk Interviews

Cytokinetics, Incorporated (CYTK) Stock Analysis: Aiming for a 48% Upside with Promising Biotech Innovations - DirectorsTalk Interviews

Click here to get full coverage on Cytokinetics Sets Key Q2 Earnings Date: What Investors Should Watch on August 7 - Stock Titan

Cytokinetics Sets Key Q2 Earnings Date: What Investors Should Watch on August 7  Stock Titan

Cytokinetics Sets Key Q2 Earnings Date: What Investors Should Watch on August 7 - Stock Titan

Click here to get full coverage on Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK) - Yahoo Finance

Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK)  Yahoo Finance

Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK) - Yahoo Finance

Click here to get full coverage on Cytokinetics, Incorporated (CYTK): the Most Oversold Pharma Stock to Buy According to Analysts - Yahoo Finance

Cytokinetics, Incorporated (CYTK): the Most Oversold Pharma Stock to Buy According to Analysts  Yahoo Finance

Cytokinetics, Incorporated (CYTK): the Most Oversold Pharma Stock to Buy According to Analysts - Yahoo Finance

Click here to get full coverage on Investors in Cytokinetics, Incorporated Should Contact Levi - GlobeNewswire

Investors in Cytokinetics, Incorporated Should Contact Levi  GlobeNewswire

Investors in Cytokinetics, Incorporated Should Contact Levi - GlobeNewswire

Click here to get full coverage on Cytokinetics Incorporated (CYTK) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Cytokinetics Incorporated (CYTK) Stock Price | Live Quotes & Charts | NASDAQ  StocksToTrade

Cytokinetics Incorporated (CYTK) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Click here to get full coverage on Cytokinetics (CYTK) Receives Reiterated 'Buy' Rating with $120 T - GuruFocus

Cytokinetics (CYTK) Receives Reiterated 'Buy' Rating with $120 T  GuruFocus

Cytokinetics (CYTK) Receives Reiterated 'Buy' Rating with $120 T - GuruFocus

Click here to get full coverage on ROSEN, LEADING INVESTOR COUNSEL, Encourages Cytokinetics, - GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Cytokinetics,  GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Cytokinetics, - GlobeNewswire

Click here to get full coverage on Noteworthy Monday Option Activity: AMC, AAP, CYTK - Nasdaq

Noteworthy Monday Option Activity: AMC, AAP, CYTK  Nasdaq

Noteworthy Monday Option Activity: AMC, AAP, CYTK - Nasdaq

Click here to get full coverage on ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, - GlobeNewswire

ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics,  GlobeNewswire

ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, - GlobeNewswire

Click here to get full coverage on Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses - Yahoo Finance

Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses  Yahoo Finance

Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses - Yahoo Finance

Click here to get full coverage on The Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Have Been Trimming Their Sales Forecasts - simplywall.st

The Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Have Been Trimming Their Sales Forecasts  simplywall.st

The Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Have Been Trimming Their Sales Forecasts - simplywall.st

Click here to get full coverage on Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts - Yahoo Finance

Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts  Yahoo Finance

Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts - Yahoo Finance

Click here to get full coverage on Shareholders who lost money in shares of Cytokinetics, - GlobeNewswire

Shareholders who lost money in shares of Cytokinetics,  GlobeNewswire

Shareholders who lost money in shares of Cytokinetics, - GlobeNewswire

Click here to get full coverage on Cytokinetics stock drops on regulatory update (CYTK:NASDAQ) - Seeking Alpha

Cytokinetics stock drops on regulatory update (CYTK:NASDAQ)  Seeking Alpha

Cytokinetics stock drops on regulatory update (CYTK:NASDAQ) - Seeking Alpha

Click here to get full coverage on INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of  GlobeNewswire

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire

Click here to get full coverage on Cytokinetics (CYTK) CEO Blum sells $190k in stock - Investing.com

Cytokinetics (CYTK) CEO Blum sells $190k in stock  Investing.com

Cytokinetics (CYTK) CEO Blum sells $190k in stock - Investing.com

Click here to get full coverage on 105,169 Stock Options at $38.67: Cytokinetics Issues Major Employee Inducement Grants - Stock Titan

105,169 Stock Options at $38.67: Cytokinetics Issues Major Employee Inducement Grants  Stock Titan

105,169 Stock Options at $38.67: Cytokinetics Issues Major Employee Inducement Grants - Stock Titan

Click here to get full coverage on CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm - Business Wire

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm  Business Wire

CYTK

Price Chart

Key Statistics

Technicals

About CYTK

Latest News

109,120 Options and 73,535 RSUs: Cytokinetics Grants Equity Inducements for New Hires - Stock Titan

Cytokinetics, Incorporated Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CYTK - Morningstar

New Highs: How interest rate cuts could boost CYTK stock - July 2025 Sentiment & High Return Trade Guides - Trung tâm Dự báo KTTV quốc gia

Advanced Charts

Top Gainers

Top Losers